Sibrafiban

From WikiMD.org
Jump to navigation Jump to search

Sibrafiban

Sibrafiban (pronounced: si-bra-fi-ban) is a pharmaceutical drug used as an anticoagulant and antiplatelet agent. It is a synthetic compound that acts as a selective inhibitor of the glycoprotein IIb/IIIa receptor, which plays a crucial role in the process of platelet aggregation.

Etymology

The name 'Sibrafiban' is derived from its chemical structure and its pharmacological action. 'Sibra' is an abbreviation of its chemical name, while 'fiban' is a common suffix used for drugs that inhibit the glycoprotein IIb/IIIa receptor.

Pharmacology

Sibrafiban works by selectively inhibiting the glycoprotein IIb/IIIa receptor on the surface of platelets. This prevents the binding of fibrinogen to the receptor, which in turn inhibits platelet aggregation and clot formation. This makes Sibrafiban an effective anticoagulant and antiplatelet agent.

Related Terms

  • Anticoagulant: A type of drug that prevents blood clots from forming.
  • Antiplatelet agent: A type of drug that inhibits the aggregation of platelets, which are small blood cells that play a key role in blood clotting.
  • Glycoprotein IIb/IIIa receptor: A receptor found on the surface of platelets that plays a crucial role in the process of platelet aggregation and clot formation.
  • Fibrinogen: A protein found in the blood that is converted into fibrin during the clotting process.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski